KR100238562B1 - 피페리딘 유도체 화합물 - Google Patents

피페리딘 유도체 화합물 Download PDF

Info

Publication number
KR100238562B1
KR100238562B1 KR1019920014727A KR920014727A KR100238562B1 KR 100238562 B1 KR100238562 B1 KR 100238562B1 KR 1019920014727 A KR1019920014727 A KR 1019920014727A KR 920014727 A KR920014727 A KR 920014727A KR 100238562 B1 KR100238562 B1 KR 100238562B1
Authority
KR
South Korea
Prior art keywords
dihydro
formula
methanoanthracene
chloro
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920014727A
Other languages
English (en)
Korean (ko)
Other versions
KR930004263A (ko
Inventor
존 오온마크트 시러스
이 잉광
애미 트레이너 다이안
제임스 루이스 조셉
Original Assignee
앤쥼 쉐이크 바쉬어
임페리알 케미칼 인더스트리즈 피엘씨
마틴 험프리스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117640A external-priority patent/GB9117640D0/en
Priority claimed from GB929207966A external-priority patent/GB9207966D0/en
Application filed by 앤쥼 쉐이크 바쉬어, 임페리알 케미칼 인더스트리즈 피엘씨, 마틴 험프리스 filed Critical 앤쥼 쉐이크 바쉬어
Publication of KR930004263A publication Critical patent/KR930004263A/ko
Application granted granted Critical
Publication of KR100238562B1 publication Critical patent/KR100238562B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
KR1019920014727A 1991-08-15 1992-08-14 피페리딘 유도체 화합물 Expired - Fee Related KR100238562B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919117640A GB9117640D0 (en) 1991-08-15 1991-08-15 Compounds
GB929207966A GB9207966D0 (en) 1992-04-10 1992-04-10 Compounds
GB9207966.4 1992-04-10
GB9117640.4 1992-04-10

Publications (2)

Publication Number Publication Date
KR930004263A KR930004263A (ko) 1993-03-22
KR100238562B1 true KR100238562B1 (ko) 2000-03-02

Family

ID=26299412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920014727A Expired - Fee Related KR100238562B1 (ko) 1991-08-15 1992-08-14 피페리딘 유도체 화합물

Country Status (16)

Country Link
US (2) US5266570A (cg-RX-API-DMAC7.html)
EP (1) EP0532178B1 (cg-RX-API-DMAC7.html)
JP (1) JP3269574B2 (cg-RX-API-DMAC7.html)
KR (1) KR100238562B1 (cg-RX-API-DMAC7.html)
AT (1) ATE144254T1 (cg-RX-API-DMAC7.html)
AU (1) AU645707B2 (cg-RX-API-DMAC7.html)
CA (1) CA2076146A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ251692A3 (cg-RX-API-DMAC7.html)
DE (1) DE69214587T2 (cg-RX-API-DMAC7.html)
FI (1) FI923664A7 (cg-RX-API-DMAC7.html)
GB (1) GB9216298D0 (cg-RX-API-DMAC7.html)
HU (1) HUT66515A (cg-RX-API-DMAC7.html)
IE (1) IE922589A1 (cg-RX-API-DMAC7.html)
IL (1) IL102808A0 (cg-RX-API-DMAC7.html)
NO (1) NO923200L (cg-RX-API-DMAC7.html)
TW (1) TW222265B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
US5514683A (en) * 1992-02-20 1996-05-07 James Black Foundation Limited Bicyclo 2,2,2!octane derivatives
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009008093A (es) * 2007-01-29 2009-08-12 Arete Therapeutics Inc Procedimientos para la preparacion de compuestos de urea sustituidos con piperidinilo.
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
KR20100016620A (ko) 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2310374B1 (en) 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
HRP20170570T1 (hr) 2008-07-31 2017-06-16 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-supstituirani-piridini kao brzo disocirajući antagonisti receptora dopamina 2
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74455C (cg-RX-API-DMAC7.html) *
US3455928A (en) * 1960-11-29 1969-07-15 Ciba Geigy Corp 9:10-dihydro-9:10-ethanoanthracen-9-alkanamides
BE610863A (fr) * 1960-11-29 1962-05-28 Ciba Geigy Procédé de préparation de nouvelles amines, entre autres de 9-amino-alcoyl-9,10-dihydro-9,10-éthano-(1,2)-anthracènes
BE674185A (cg-RX-API-DMAC7.html) * 1961-10-10
FR176F (cg-RX-API-DMAC7.html) * 1965-05-19
US3489799A (en) * 1967-09-26 1970-01-13 Ciba Geigy Corp Ethano-anthracenes
ES367292A1 (es) * 1968-05-16 1971-05-01 Ciba Geigy Procedimiento para la obtencion de 9-(aminoalquilo)-9,10- dihidro - 9,10-etanoantracenos sustituidos.
US3706765A (en) * 1969-01-03 1972-12-19 Ciba Geigy Corp Hydroxyethano-anthracenes
CH532553A (de) * 1969-03-25 1973-01-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen N-substituierten 9-NAminoalkyl)-12-acyloxy-9,10-dihydro-9,10-äthano-anthrazenen
DE2021668A1 (de) * 1969-05-10 1970-11-19 Ciba Geigy Neue Amine und Verfahren zu ihrer Herstellung
US3795676A (en) * 1970-10-01 1974-03-05 Sandoz Ag 7-substituted pleiadenes and 8-substituted dibenzoheptalenes
US3870796A (en) * 1970-11-27 1975-03-11 Ciba Geigy Corp Pharmaceutical preparation
US4045580A (en) * 1971-02-23 1977-08-30 Ciba-Geigy Corporation Pharmaceutical preparation using 9-(2-hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes as antidepressants
US4017542A (en) * 1971-02-23 1977-04-12 Ciba-Geigy Corporation 9-(2-Hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes and salts thereof
JPS5911576B2 (ja) * 1975-07-07 1984-03-16 住友化学工業株式会社 新規なメタノ−アントラセン誘導体の製造法
GB1508669A (en) * 1974-12-13 1978-04-26 Sumitomo Chemical Co Methanoanthracene derivative and a process for the preparation thereof
US4358620A (en) * 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
JPS527972A (en) * 1975-07-07 1977-01-21 Sumitomo Chem Co Ltd Process for preparing novel morpholine derivatives
JPS5268170A (en) * 1975-12-03 1977-06-06 Sumitomo Chem Co Ltd Preparation of novel methano-anthracene derivatives
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
JPS5910654B2 (ja) * 1976-04-07 1984-03-10 住友化学工業株式会社 新規なメタノ−アントラセン誘導体
JPS597709B2 (ja) * 1976-07-05 1984-02-20 住友化学工業株式会社 新規なモルホリン誘導体及びその製造法
US4318926A (en) * 1979-08-14 1982-03-09 Ciba-Geigy Corporation Method of curing or alleviating herpes infections and pharmaceutical compositions suitable therefor
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
GB9117639D0 (en) 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JP3005176U (ja) 1994-05-30 1994-12-13 勝治 都竹 介護用シャツ

Also Published As

Publication number Publication date
FI923664A0 (fi) 1992-08-14
KR930004263A (ko) 1993-03-22
DE69214587D1 (de) 1996-11-21
ATE144254T1 (de) 1996-11-15
EP0532178B1 (en) 1996-10-16
HU9202642D0 (en) 1992-10-28
JPH05239026A (ja) 1993-09-17
HUT66515A (en) 1994-12-28
CZ251692A3 (en) 1993-02-17
FI923664L (fi) 1993-02-16
AU645707B2 (en) 1994-01-20
NO923200D0 (no) 1992-08-14
DE69214587T2 (de) 1997-03-20
US5266570A (en) 1993-11-30
AU2101592A (en) 1993-02-18
CA2076146A1 (en) 1993-02-16
NO923200L (no) 1993-02-16
IL102808A0 (en) 1993-01-31
IE922589A1 (en) 1993-02-24
US5455246A (en) 1995-10-03
JP3269574B2 (ja) 2002-03-25
TW222265B (cg-RX-API-DMAC7.html) 1994-04-11
FI923664A7 (fi) 1993-02-16
EP0532178A1 (en) 1993-03-17
GB9216298D0 (en) 1992-09-16

Similar Documents

Publication Publication Date Title
KR100238562B1 (ko) 피페리딘 유도체 화합물
JP4493503B2 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
JPH05148228A (ja) 新規１，４−二置換ピペリジン、その製法と治療用途
JPH03169860A (ja) 置換ｎ―ベンジルピペリジンアミド
JPS61155358A (ja) ジアリール酪酸誘導体
EP1598346B1 (en) Process for producing acid adduct salt of polyacidic base compound
US4243666A (en) 4-Amino-2-piperidino-quinazolines
JPH0699420B2 (ja) 水素添加された１−ベンゾオキサシクロアルキルピリジンカルボン酸化合物，その製造方法及び該化合物を含む医薬製剤
EP0315405A1 (en) 4-phenyl-4-(N-(2-fluorophenyl)amido) piperidine derivatives
JP3169188B2 (ja) カルバミン酸誘導体及びその製造方法
US3914238A (en) 4-Aryl-{60 -(1,4-benzodioxan-2-yl)-4-hydroxy-1-piperidineethanols
US5668131A (en) Substituted aminoalkylaminopyridines
US8604190B2 (en) Hetero isonipecotic modulators of vanilloid VR1 receptor
EP1087954A1 (en) Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US5093336A (en) 6- and 7-deoxyforskolin and derivatives thereof
EP0223124B1 (en) Substituted aminosulfonyl 6-nitrobenzoic-esters or amides, processes for their preparation and pharmaceutical compositions containing them
US4029786A (en) Morpholine derivatives for treating depression
KR101191277B1 (ko) ＩＫＫ-β 저해제로 작용하는 2-아자사이클릭아미노-4-페닐피리미딘 유도체
US4999351A (en) 7-aryl and heteroaryl ethers of desacetylforskolin
JP2846070B2 (ja) カルボキシイミダミド誘導体
JPH03294277A (ja) ピペリジン誘導体
US5177207A (en) 7-aryl and heteroaryl ethers of desacetylforskolin
AP521A (en) Piperidinyl compounds
JPWO2000078719A1 (ja) ジヒドロピリジン誘導体
HK1156947A (en) Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20021015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20021015

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000